EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

OBJECTIVES: To develop the European League Against Rheumatism (EULAR) recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis. METHODS: An expert consensus group was formed consisting of rheumatologists, nephrologists and specialists in internal medicine repres...

Full description

Bibliographic Details
Main Authors:	Hellmich, B, Flossmann, O, Gross, W, Bacon, P, Cohen-Tervaert, J, Guillevin, L, Jayne, D, Mahr, A, Merkel, P, Raspe, H, Scott, D, Witter, J, Yazici, H, Luqmani, R
Format:	Journal article
Language:	English
Published:	2007

Similar Items

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
by: Mukhtyar, C, et al.
Published: (2008)

EULAR recommendations for the management of large vessel vasculitis.
by: Mukhtyar, C, et al.
Published: (2009)

Eular recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis
by: Hellmich, B, et al.
Published: (2006)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
by: Luqmani, R, et al.
Published: (2007)

Eular recommendations for vasculitis
by: Luqmani, R, et al.
Published: (2007)

EULAR recommendations for the management of primary small and medium vessel vasculitis.
by: Mukhtyar, C, et al.
Published: (2009)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
by: Mukhtyar, C, et al.
Published: (2006)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
by: Merkel, P, et al.
Published: (2009)

Nomenclature and classification of vasculitis - update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS).
by: Luqmani, R, et al.
Published: (2011)

Current evidence of factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis. A systematic review for the EULAR systemic vasculitis task force
by: Mukhtyar, C, et al.
Published: (2007)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
by: Yates, M, et al.
Published: (2016)

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis.
by: Basu, N, et al.
Published: (2010)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
by: Pearce, F, et al.
Published: (2017)

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
by: Yates, M, et al.
Published: (2016)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
by: Flossmann, O, et al.
Published: (2006)

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis
by: Yates, M, et al.
Published: (2016)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
by: Robson, J, et al.
Published: (2014)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
by: Walsh, M, et al.
Published: (2011)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
by: Basu, N, et al.
Published: (2014)

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
by: De Groot, K, et al.
Published: (2005)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
by: Yates, M, et al.
Published: (2017)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Robson, J, et al.
Published: (2017)

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis
by: Despina Michailidou, et al.
Published: (2022-06-01)

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
by: Guerry, M, et al.
Published: (2012)

The future of damage assessment in vasculitis.
by: Seo, P, et al.
Published: (2007)

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).
by: Craven, A, et al.
Published: (2013)

Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis
by: Luqmani, R, et al.
Published: (2007)

Anti-neutrophil cytoplasmic autoantibodies associated vasculitis – Clinical profile and outcomes
by: Kavya Devi Nunna, et al.
Published: (2018-01-01)

Clinical features of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis in French children
by: Salomon R, et al.
Published: (2011-09-01)

Outcome in systemic vasculitis.
by: Luqmani, R, et al.
Published: (1998)

Development of comprehensive disease assessment in systemic vasculitis.
by: Flossmann, O, et al.
Published: (2007)

Development of comprehensive disease assessment in systemic vasculitis.
by: Flossmann, O, et al.
Published: (2008)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
by: Luqmani, R, et al.
Published: (2017)

Vasculitis integrated total assessment log (VITAL): A system for clinical evaluation of vasculitis.
by: Luqmani, R, et al.
Published: (1996)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
by: Luqmani, R, et al.
Published: (2017)

Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials
by: Luqmani, R, et al.
Published: (2001)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
by: Robson, J, et al.
Published: (2017)

Outcome in small-vessel systemic vasculitis.
by: Luqmani, R, et al.
Published: (2006)

Comparison of disease activity measures for ANCA-associated vasculitis.
by: Merkel, P, et al.
Published: (2004)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
by: Suppiah, R, et al.
Published: (2011)